M. Mokyr

发表

Activation of suppressor T cells by tumour cells and specific antibody

R. Gershon, M. Mokyr, M. Mitchell, 1974, Nature.

Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor

L. Gorelik, M. Mokyr, A. Prokhorova, 1994, Cancer Immunology, Immunotherapy.

The Xeroderma Pigmentosum Group E Gene Product DDB2 Activates Nucleotide Excision Repair by Regulating the Level of p21Waf1/Cip1

P. Raychaudhuri, Tanya Stoyanova, T. Yoon, 2007, Molecular and Cellular Biology.

Melphalan-Induced Expression of IFN-β in MOPC-315 Tumor-Bearing Mice and Its Importance for the Up-Regulation of TNF-α Expression1

V. Jovasevic, M. Mokyr, 2001, The Journal of Immunology.

Role of AntitumorImmunityin Cyclophosphamide-inducedRejectionof Subcutaneous Nonpalpable MOPC-315 Tumors1

M. Mokyr, J. Hengst, 2006 .

Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas

M. Mokyr, J. Wise, S. Dray, 2004, Cancer Immunology, Immunotherapy.

Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor

S. Ben-Efraim, M. Mokyr, S. Dray, 2004, Cancer Immunology, Immunotherapy.

Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor

S. Ben-Efraim, M. Mokyr, S. Dray, 2004, Cancer Immunology, Immunotherapy.

Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy.

M. Mokyr, S. Dray, 1987, Cancer investigation.

IMMUNOMODULATION BY A LOW DOSE OF CYCLOPHOSPHAMIDE AS THE PRIMARY MECHANISM FOR THE CURE OF MICE BEARING A LARGE METASTATIC MOPC-315 TUMOR1

M. Mokyr, S. Dray, 1985 .

; Realizationof theTherapeuticPotentialof CTLA-4Blockadein Low-Dose Chemotherapy-treated Tumor-bearing Mice1

J. Bluestone, L. Gorelik, T. Kalinichenko, 2006 .

Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.

J. Bluestone, L. Gorelik, T. Kalinichenko, 1998, Cancer research.

Melphalan-induced up-regulation of B7–1 surface expression on normal splenic B cells

P. Raychaudhuri, V. Jovasevic, M. Mokyr, 2003, Cancer Immunology, Immunotherapy.

Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors

M. Mokyr, K. Russo, S. Dray, 1993, Cancer Immunology, Immunotherapy.

Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy

M. Mokyr, K. Russo, S. Dray, 2005, Cancer Immunology, Immunotherapy.

Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas.

M. Mokyr, S. Dray, M. Laude, 1991, Cancer research.

Enhancement of the effectiveness of Lyt-2+ T-cells for adoptive chemoimmunotherapy by short-term exposure of tumor-bearer spleen cells to polyethylene glycol and/or melphalan.

M. Mokyr, J. Wise, S. Dray, 1989, Cancer research.

Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy

M. Mokyr, L. Weiskirch, Y. Bar-Dagan, 1994, Cancer Immunology, Immunotherapy.

Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule

J. Bluestone, J. Leiden, E. Barr, 1996, Cancer Immunology, Immunotherapy.

Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.

J. Davis, M. Mokyr, M. Mitchell, 1977, The Journal of clinical investigation.

Purification of tumor‐specific antigens. An overview of the relevance to human colon carcinoma

L. Rutzky, N. Pellis, B. Kahan, 1975, Cancer.

Importance of IL-10 for CTLA-4-Mediated Inhibition of Tumor-Eradicating Immunity1

J. Bluestone, L. Gorelik, V. Jovasevic, 2004, The Journal of Immunology.

Inhibition of Tumor-Eradicating Immunity Importance of IL-10 for CTLA-4-Mediated and

J. Bluestone, L. Gorelik, V. Jovasevic, 2004 .

Signaling through CD40 enhances cytotoxic T lymphocyte generation by CD8+ T cells from mice bearing large tumors

M. Mokyr, Manjula Donepudi, Dong D. Quach, 1999, Cancer Immunology, Immunotherapy.

Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.

M. Mokyr, Q. Ye, 1985, Cancer research.

Importance of signaling via the IFN-α/β receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor

Aaron T. Place, M. Mokyr, J. Artwohl, 2006, Cancer Immunology, Immunotherapy.

Limited importance of CD40/CD40L interaction in the B7-dependent generation of anti-MOPC-315 cytotoxic T lymphocyte activity by tumor bearer splenic cells stimulated in vitro in the presence of tumor necrosis factor

T. Kalinichenko, M. Mokyr, 1998, Cancer Immunology, Immunotherapy.

Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers

M. Mokyr, M. Rubin, 2005, Cancer Immunology, Immunotherapy.

Melphalan and Other Anticancer Modalities Up-Regulate B7-1 Gene Expression in Tumor Cells1

J. Bluestone, Dorothy K. Sojka, M. Mokyr, 2000, The Journal of Immunology.

TumorUp-Regulate B 7-1 Gene Expression in Melphalan and Other Anticancer Modalities and

J. Bluestone, Dorothy K. Sojka, M. Mokyr, 2000 .

Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.

J. Bluestone, A. Sharpe, M. Mokyr, 1999, Journal of Immunology.

T Cell-Dependent Mechanism + CD 8 B 7-1-Transfected P 815 Tumor Cells Via a Contribute to the Eradication of Host B 7-1 and B 7-2 Costimulatory Molecules and

J. Bluestone, A. Sharpe, M. Mokyr, 1999 .

Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism.

L. Gorelik, T. Kalinichenko, M. Mokyr, 1997, Cellular immunology.

Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.

J. Bluestone, L. Gorelik, T. Kalinichenko, 1998, Journal of immunology.

Large MOPC-315 Tumor Tumor-Eradicating Immunity by Mice Bearing a Melphalan-Induced Acquisition of Importance of the B 7-2 Molecule for Low Dose

J. Bluestone, L. Gorelik, T. Kalinichenko, 1998 .

Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

M. Colvin, M. Colvin, M. Mokyr, 1985, International journal of immunopharmacology.

Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers

E. Barker, M. Mokyr, L. Weiskirch, 2005, Cancer Immunology, Immunotherapy.

Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor

E. Barker, M. Mokyr, L. Weiskirch, 2005, Cancer Immunology, Immunotherapy.

Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.

B. Takesue, M. Mokyr, J. Pyle, 1990, Cancer research.

Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.

E. Barker, M. Mokyr, J. Wise, 1989, Cancer research.

Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.

E. Barker, B. Takesue, M. Mokyr, 1989, Cancer research.

Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.

E. Barker, M. Mokyr, 1988, Cancer research.

Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.

B. Takesue, M. Mokyr, Mary M. Bartik, 1987, International journal of immunopharmacology.

Effect of imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno) on immunity in patients with malignant melanoma.

H. Bruckner, M. Mokyr, M. Mitchell, 1974, Cancer research.

Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication.

J. Bluestone, M. Mokyr, A. Prokhorova, 1994, Journal of Immunology.

Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan‐treated BALB/C mice bearing a large MOPC‐315 tumor

M. Mokyr, L. Weiskirch, 1992, International journal of cancer.

Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.

M. Mokyr, S. Dray, J. C. Hengst, 1981, Cancer research.

Activation of lymphoid cells by BCG in vitro.

M. Mokyr, M. Mitchell, 1975, Cellular immunology.

On the mode of action of BCG.

I. Gery, M. Mokyr, M. Mitchell, 1973, Nature: New biology.

Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy

M. Mokyr, S. Dray, 1989, Medical oncology and tumor pharmacotherapy.

Cooperation between cyclophosphamide cytotoxic effects and host anti-tumor immunity in the cure of mice bearing large size sc mopc-315 tumors. Abstr.

M. Mokyr, S. Dray, J. C. Hengst, 1981 .

Specific T cell-dependent, antigen-antibody mediated suppression of macrophages: abrogation by nonspecifically stimulated T cells.

R. Gershon, M. Mokyr, M. Mitchell, 1977, Journal of immunology.

The development of in vitro and in vivo anti-tumor cytotoxicity in noncytotoxic, MOPC-315-tumor-bearer, spleen cells “educated” in vitro with MOPC-315 tumor cells

D. Braun, H. Reiter, M. Mokyr, 1978, Cancer Immunology, Immunotherapy.

Cytophilic antibodies in man.

M. Mokyr, M. Mitchell, G. Aspnes, 1973, Annals of internal medicine.

Mechanism of Melphalan-Induced B7-1 Gene Expression in P815 Tumor Cells1

J. Bluestone, P. Raychaudhuri, M. Mokyr, 2001, The Journal of Immunology.

Expression in P 815 Tumor Cells Mechanism of Melphalan-Induced B 7-1 Gene Bluestone and

J. Bluestone, P. Raychaudhuri, M. Mokyr, 2001 .

Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy

R. Hendricks, M. Mokyr, M. Ahn, 2005, Cancer Immunology, Immunotherapy.

Immunomodulation by Cyclophosphamide and its Effect on Eradication of Established Tumors

M. Mokyr, S. Dray, 1984 .

Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.

M. Mokyr, S. Dray, J. C. Hengst, 1982, Cancer research.

Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization.

D. Przepiorka, M. Mokyr, S. Dray, 1979, Cancer research.

Cyclophosphamide-inducedAppearanceof ImmunopotentiatingT-Cells in the Spleens of Mice Bearinga Large MOPC-315Tumor1

M. Mokyr, Q. Ye, 2006 .

Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers

M. Mokyr, Mary M. Bartik, Barbara A. Baumgartel-Scofield, 2005, Cancer Immunology, Immunotherapy.

Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.

M. Mokyr, M. Ahn, Mary M. Bartik, 1989, Cancer research.

Ability of cyclophosphamide in the absence of cross-linking activity to exert the immunomodulatory effect required for the cure of mice bearing a large MOPC-315 tumor.

M. Colvin, M. Mokyr, R. Brundrett, 1986, Cancer research.

Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.

M. Mokyr, S. Dray, J. C. Hengst, 1980, Cancer research.

Stimulation of lymphoid cells by components of BCG.

I. Kahane, M. Mokyr, M. Mitchell, 1975, Journal of the National Cancer Institute.

Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth

M. Mokyr, S. Dray, R. Bocian, 2004, Cancer Immunology, Immunotherapy.

Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells.

L. Gorelik, M. Mokyr, Y. Bar-Dagan, 1996, Journal of immunology.

Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon γ in the therapeutic outcome

L. Gorelik, M. Mokyr, 1995, Cancer Immunology, Immunotherapy.

Norepinephrine-Mediated Inhibition of Antitumor Cytotoxic T Lymphocyte Generation Involves a β-Adrenergic Receptor Mechanism and Decreased TNF-α Gene Expression

V. Kalinichenko, R. Cohen, D. A. Chambers, 1999, The Journal of Immunology.

Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan

E. Barker, M. Mokyr, 2004, Cancer Immunology, Immunotherapy.

Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers

E. Barker, M. Mokyr, 2004, Cancer Immunology, Immunotherapy.

Anti-metastatic activity of hapten-modified autologous tumor cell vaccine in an animal tumor model

D. Felnerova, Dorothy K. Sojka, M. Mokyr, 2002, Cancer Immunology, Immunotherapy.

B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells

Dorothy K. Sojka, M. Mokyr, R. N. La Motte, 2000, Cancer Immunology, Immunotherapy.

Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.

M. Mokyr, S. Dray, 1983, Cancer research.

Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression.

V. Jovasevic, M. Mokyr, 2001, Journal of immunology.

Importance of timing of cyclophosphamide (cy) therapy for curing mopc-315 tumor-bearing mice. Abstr.

M. Mokyr, S. Dray, J. C. Hengst, 1980 .

Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression.

V. Kalinichenko, R. Cohen, D. A. Chambers, 1999, Journal of immunology.

Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.

L. Gorelik, M. Mokyr, A. Prokhorova, 1995, Journal of immunology.

Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma

R. Perlman, R. Cohen, D. A. Chambers, 1995, Cancer Immunology, Immunotherapy.

Opposite effects of different strains or batches of same strain of BCG on in vitro generation of syngeneic and allogeneic antitumor cytotoxicity.

J. Bennett, D. Braun, M. Mokyr, 1980, Journal of the National Cancer Institute.

Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation.

D. Braun, M. Mokyr, S. Dray, 1979, Cancer research.

Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.

D. Braun, M. Mokyr, S. Dray, 1978, Cancer Research.

Effect of Polyethylene Glycol 6000 on the Generation of Antitumor Cytotoxicity in MOPC-315 Tumor Bearer Spleen Cells Cultured in the Presence or Absence of Inactivated Stimulator Tumor Cells 1

D. Przepiorka, M. Mokyr, S. Dray, 2006 .

Effect of polyethylene glycol 6000 on the generation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells cultured in the presence or absence of inactivated stimulator tumor cells.

D. Przepiorka, M. Mokyr, S. Dray, 1980, Cancer research.

Effect of Polyethylene Glycol 6000 on the Generation of Antitumor Cytotoxicity in MOPC-315 Tumor Bearer Spleen Cells Cultured in the Presence or Absence of Inactivated Stimulator Tumor Cells1

D. Przepiorka, M. Mokyr, S. Dray, 2006 .

Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor

M. Mokyr, J. Pyle, S. Dray, 2004, Cancer Immunology, Immunotherapy.

Mode of action of polyethylene glycol 6000 in potentiating the in vitro generation of antitumor cytotoxicity by MOPC-315 tumor bearer spleen cells.

D. Przepiorka, M. Mokyr, S. Dray, 1982, Cancer research.

to in Vitro Activation Bearer Spleen Cells by Depletion of Glass-adherent Cells Prior Augmentation of Antitumor Cytotoxicity in MOPC-315 Tumor

D. Braun, M. Mokyr, S. Dray, 2013 .

Augmentation of Antitumor Cytotoxicity in MOPC-315 Tumor Bearer Spleen Cells by Depletion of Glass-adherent Cells Prior to in Vitro I

D. Braun, M. Mokyr, S. Dray, 2006 .

Analysis and reversal of the inhibition of cytophilic antibody receptors produced by antibody.

D. Goldwater, M. Mokyr, M. Mitchell, 1975, Cancer research.

Can the bad guys be defeated?

M. Mokyr, 1988, Cancer investigation.

Specific inhibition of receptors for cytophilic antibody on macrophages by isoantibody.

M. Mokyr, M. Mitchell, 1972, Cancer research.

Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.

J. Bluestone, A. Sharpe, M. Mokyr, 1998, Journal of immunology.

Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.

J. Bluestone, K. Newell, M. Mokyr, 1994, Journal of immunology.

Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.

J. Bluestone, K. Newell, M. Mokyr, 1993, Journal of immunology.

Progression of the immune response to solubilized tumor antigens.

N. Pellis, J. Babcock, B. Kahan, 1978, Immunological communications.

Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy

M. Mokyr, L. Weiskirch, Y. Bar-Dagan, 1994, Cancer Immunology, Immunotherapy.

Specific and non‐specific immunologic mechanisms of tumor growth facilitation

H. Yamagishi, N. Pellis, B. Kahan, 1980, Cancer.